Urology

Baylor St. Luke's Medical Center was recently recognized as High Performing in Urology by U.S. News & World Report. We have more than 13 clinical urologists performing over 2,800 inpatient and outpatient procedures each year.

High Standard of Care for Urology and Kidney Disorders

At Baylor St. Luke’s Medical Center, our patients receive care from highly educated and experienced nurses with expertise in urologic nursing. Men undergoing a radical prostatectomy are better able to manage pain and know what to expect after the surgery because of research by our urologic nursing team. The nurses provide thorough and consistent education for the patient and his significant other or caregiver.
The urology unit also is among those meeting a hospital-wide goal to minimize urinary tract infections through bladder scans. Aimed at maintaining and improving bladder function, this non-invasive procedure, performed at the bedside by a nurse, reduces catheter use.

Conditions & Treatments

  • Bladder cancer
  • Erectile dysfunction
  • Genitourinary reconstruction
  • Genitourinary trauma
  • Iontophorepic therapy for Peyronie's disease
  • Kidney cancer and kidney-sparing surgery
  • Kidney transplantation
  • Laser surgery
  • Minimally invasive surgery
  • Pelvic organ prolapse
  • Prostate cancer
  • Robotic surgery
  • Stress incontinence in women
  • Testicular cancer
  • Urinary incontinence
  • Urinary obstructions
    • Benign prostate hyperplasia (BPH)
    • Kidney stones
    • Ureter disorders
    • Ureteral obstruction
    • UPJ (ureteropelvic junction)
    • Urethral strictures
  • Voiding disorders
  • Urodynamic evaluation

Nationally Ranked for Genitourinary Cancer Care

Recognized as one of the top hospitals for cancer care in the nation, Baylor St. Luke’s Medical Center brings innovative treatments from the lab to the bedside to stop cancer in its tracks faster than ever before. The Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine is one of only three NCI-designated Comprehensive Cancer Centers in Texas and is able to contribute vital advances to cancer research through national funding. The adult private clinical practice for the Duncan Cancer Center is a department of Baylor St. Luke’s.. Our team is highly skilled in the treatment of many types of genitourinary cancer, including bladder cancer, testicular cancer, and prostate cancer.

CyberKnife Offered at Baylor St. Luke’s

This non-invasive alternative to surgery is utilized to treat cancerous and non-cancerous tumors throughout the body, including the prostate. Patients require no anesthesia, and this option treats many tumors and lesions that may have been previously considered inoperable or untreatable.
CyberKnife offers sub-millimeter precision, delivering maximum dosages with the ability to protect healthy tissue. Patients treated with CyberKnife reported a return to normal urinary and bowel function by six months post-procedure.
CyberKnife® is a non-invasive alternative to surgery for cancerous and non-cancerous tumors.
Seth P. Lerner, MD, FACS

Professor of Urology, Baylor College of Medicine

Urology Research and Innovation at Baylor St. Luke’s

As part of our affiliation with Baylor College of Medicine, our urology team takes part in innovative research that we translate into state-of-the-art clinical options for those we serve. Here are some of the innovative contributions by physicians at Baylor St. Luke’s.
Applying Genomics to Bladder Cancer Treatment
Dr. Seth Paul Lerner, urologist at Baylor St. Luke’s, and his colleagues at Baylor College of Medicine study the genomic underpinnings of diverse characteristics in patients with muscle invasive bladder cancer as part of the Cancer Genome Atlas Research Network.
He and his team found a connection between cancer subtype and outcomes. “We were able to show that mutation signatures, molecular subtypes, load of new cancer-associated molecules and known clinical and pathological factors have a very clear influence on overall patient survival,” says Dr. Lerner.
Taking these factors into account allows for more personalized and effective treatment for patients.
“Of the 11 patients we identified as having a neuronal subtype, all of those evaluable for objective response responded to the treatment (two complete response, six partial response), or 72% overall. This translated to a very high survival probability which is unprecedented in advanced bladder cancer,” says Lerner.
“Although this is a small group of patients, it is very exciting to see that our basic research can be directly translated to the clinical setting allowing us to determine which subtype of bladder cancer has a better chance to respond well to a specific treatment.”
Fertility Preservation in Men on Testosterone Therapy
According to Dr. Larry Lipshultz, Baylor St. Luke’s urologist and Chief of the Scott Department of Urology’s Division of Male Reproductive Medicine and Surgery at Baylor College of Medicine, “low-dose hCG may be beneficial for men in their reproductive years requiring testosterone replacement therapy.”
Based on his data analysis and research, low-dose human chorionic gonadotropin, or hCG, may preserve spermatogenesis in men with hypogonadism treated with intramuscular or transdermal testosterone replacement therapy.

His suggested regimen for men hoping for a pregnancy now:

  • Subcutaneous hcG at about 3,000 U, three times per week
  • Clomiphene therapy
  • Check follicle-stimulating hormone (FSH) levels at four months
    • If FSH levels aren’t adequate, stop clomiphene and replace with FSH

His suggested regimen for men hoping for a future pregnancy:

  • Subcutaneous hcG at about 500 U, three times a week
  • Cycle off of testosterone twice a year at a rate of about 3,000 U, three times a week for four weeks, in addition to 15 mg of clomiphene therapy daily

His suggested regimen for men just looking to prevent testicular atrophy:

  • Subcutaneous hcG at about 1,500 U, once a week
  • Cycle off of testosterone twice a year at a rate of about 3,000 U, three times a week for four weeks, in addition to 15 mg of clomiphene therapy daily
These treatment guidelines have achieved remarkable results. “To date, we have not had any patients who did not return to baseline,” says Dr. Lipshultz.
Clinical Trials Testing Drug and Treatment Efficacy
Novel Treatment for Patients With Low-Grade UTUC Spares Kidneys
Dr. Seth Lerner, urologist at Baylor St. Luke’s, recently shared the findings of Baylor College of Medicine’s phase III OLYMPUS trial. A new formulation of a chemotherapy drug resulted in a 59% complete response rate among patients with unresectable low-grade upper tract urothelial cancer, allowing for a minimally invasive alternative to kidney removal. Read more via OncLive.com.
Targeting Estrogen Receptors to Reduce Bladder Cancer Recurrence
Patients with low/intermediate-risk bladder cancer often experience recurrences. In the second phase of this study, researchers, including Baylor St. Luke’s and Baylor College of Medicine urologist Dr. Guilherme Godoy, sought to reduce the rate of recurrence by prescribing oral tamoxifen. This prototypic selective estrogen receptor modulator (SERM) was given to prevent carcinogenesis in these patients. Findings revealed that this regimen reduced and even eliminated marker lesions in participants. Read the full study here, or read more via Medscape.com.
Uncovering a Connection Between Shift Work and Hypogonadism
A group of researchers, including Dr. Larry Lipshultz, Baylor St. Luke’s urologist and Chief of the Scott Department of Urology’s Division of Male Reproductive Medicine and Surgery at Baylor College of Medicine, found a correlation between shift work and quantitative Androgen Deficiency in the Aging Male (qADAM), as well as reduced testosterone levels.
Additionally, those who worked unconventional hours and had a diagnosis of shift work sleep disorder (SWSD) had even lower qADAM scores and testosterone levels. Researchers believe that irregular sleep patterns is the cause of the hypogonadal symptoms. Find the full study here, or read more via UroToday.com.
Advocating for Collaboration Between Cooperative Groups
This year, Baylor St. Luke’s urologist Dr. Seth Lerner spoke on the unique benefits of the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), the Southwest Oncology Group (SWOG), and the Cancer Therapy Evaluation Program (CTEP). With a focus on how cooperative groups can improve patient outcomes and provide innovative knowledge to everyone in the field, Dr. Lerner advocated for physicians and researchers alike to utilize these resources. Read more via UroToday.com.
Seth P. Lerner, MD, FACS

Professor of Urology, Baylor College of Medicine